EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Baseline FDG PET/CT–Defined Axillary Burden Predicts Axillary Pathologic Complete Response After Neoadjuvant Therapy in Breast Cancer

Mehmet Tarık Tatoğlu, İlker Nihat Ökten, Ebru Ibisoglu, Tuçe Söylemez Akkurt, Ferda Yerdelen Tatoğlu, Hatice Uslu, Hakan Baysal

Nuklearmedizin - NuclearMedicine · 2026-06-01 · 65 (03) · 207-216

DOI: 10.1055/a-2825-4883 ↗
AbstractBibliografische Angaben

Abstract

Abstract Aim Predicting axillary pathologic complete response (pCR) after neoadjuvant systemic therapy (NST) may enable risk-adapted axillary management in clinically node-positive breast cancer (BC), but practical baseline PET-derived predictors are limited. Methods Single-center retrospective cohort of consecutive cN+, M0 patients with baseline [18F]FDG PET/CT–reported axillary nodal metastasis treated with NST and surgery (complete-case n=115). Axillary pCR was defined as no residual invasive carcinoma in axillary lymph nodes; isolated tumor cells and/or micrometastases were classified as non-pCR. Two prespecified ridge-penalized logistic models combined routine clinical variables with baseline PET-defined axillary burden as (i) hypermetabolic ALN count (Model A) or (ii) limited (1–3) versus advanced (≥4) burden group (Model B). Stratified 5-fold cross-validation generated out-of-fold (OOF) predictions; AUC, Brier score, and logistic recalibration slope/intercept were bootstrapped on OOF predictions (2000 resamples). Results Axillary pCR occurred in 59/115 (51.3%). Discrimination was good: AUC 0.80 (95% CI 0.72–0.88) for Model A and 0.79 (95% CI 0.71–0.87) for Model B. Calibration was acceptable (bootstrap-mean slope/intercept ≈1.10/0.04 and 1.08/0.03, respectively). Greater baseline PET-defined axillary extent was associated with lower odds of pCR; molecular subtype and neoadjuvant anti-HER2 therapy remained strongly associated with response. Conclusion Prespecified ridge models combining routine clinical variables with baseline [18F]FDG PET/CT–defined axillary burden showed good internal performance for predicting axillary pCR. External validation is required before response-adapted clinical use.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →